Fennec Pharmaceuticals Inc.
Hot onWhy it's trendingX mentions rising faster than the marketBacked by solid revenue growthPrice and volume picking up$9.98-3.6%YTD+28.9%1Y+15.5%
Price updated 7h ago·X counts updated 5d ago
On X
The complete picture of $FENC on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
4X posts · last 7 days
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $FENC — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $FENC.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $FENC
Neutral — Specialty biopharma commercializing PEDMARK, the only FDA-approved therapy to prevent cisplatin-induced hearing loss in pediatric cancer patients.
Top industry ETF
$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-41.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-9.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-11.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
8.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-54.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
92.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$0.05$0.02+150.0%
Q1 2026May 14, 2026$0.01$-0.02+150.0%
Q4 2025Mar 24, 2026$-0.17$0.03-666.7%
Q3 2025Nov 13, 2025$-0.02$-0.08+75.0%
Next earningsThu, Nov 12·consensus EPS $0.09
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$15.1M+72.6%96.2%-0.8%$0.01$2.4M
Q4 FY25$13.8M+73.8%87.2%-18.7%$-0.17$-6.0M
Q3 FY25$12.5M+78.7%94.7%-1.6%$-0.02$1.5M
Q2 FY25$9.7M+32.9%90.0%-28.3%$-0.12$-3.7M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$72.6M$70.9M – $73.9M$0.28$0.20 – $0.375
FY27$103.1M$98.1M – $106.4M$0.94$0.69 – $1.165
FY28$138.9M$110.6M – $155.5M$1.64$0.94 – $2.004
FY29$194.1M$175.8M – $204.3M$2.77$2.43 – $2.962
FY30$227.7M$206.3M – $239.7M$3.41$3.00 – $3.652
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.57%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-10.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+10.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 17.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.105-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
8-KOfficer or director changeMay 188-K — Item 5.02: Officer or director change
8-KOfficer or director changeApr 288-K — Item 5.02: Officer or director change
+ 13 other (6 13Gs · 3 routine 8-Ks · 2 10-Qs · 1 S-8) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Adherex Technologies (NASDAQ:FENC) and SCYNEXIS (NASDAQ:SCYX) Financial SurveyFennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call TranscriptAdherex Technologies Q2 Earnings Call Highlights
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $FENC on X in the last 7 days.